- Home
- ZURA vs SI Comparison
ZURA vs SI Comparison
Compare ZURA & SI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | SI |
|---|---|---|
| Founded | 2022 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 376.2M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZURA | SI |
|---|---|---|
| Price | $3.96 | $19.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $19.00 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 4.7M | 86.6K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,317,000.00 |
| Revenue This Year | N/A | $44.61 |
| Revenue Next Year | N/A | $29.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.63 |
| 52 Week Low | $3.25 | $10.92 |
| 52 Week High | $7.25 | $24.60 |
Technical Indicators
Market Signals| Indicator | ZURA | SI |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 52.60 |
| Support Level | $3.26 | $17.97 |
| Resistance Level | $6.05 | $20.24 |
| Average True Range (ATR) | 0.53 | 0.98 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 45.70 | 51.55 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.